Case study

Evaluating the potential for Sensyne in the US healthcare market – our collaboration with Jefferson Health

January 15, 2020

The US currently spends approximately 18%of its GDP on healthcare, compared to 10%in the UK. There are significant potential opportunities to introduce healthcare innovations that have been developed and validated by Sensyne Health, working in partnership with the NHS, to be exported to the US. In January 2019 Sensyne Health entered into a collaboration with Jefferson Health’s Strategic Ventures arm to undertake a clinical and health-economic evaluation of Sensyne Health’s digital health products to determine their potential in the US market.

Purpose

One of the largest healthcare providers in Pennsylvania and New Jersey and the fastest growing health system in the US, Philadelphia-based Jefferson Health, has 14 hospitals with 2,800 beds,6,000 physicians and 7,000nursing staff. The system includes the Sidney Kimmel Cancer Centre and is affiliated with the Thomas Jefferson University. JeffersonHealth has a track record of supporting digital health businesses seeking a route into the US market through collaboration and shares an interest in the target disease areas on which Sensyne Health is focused.

The work

As part of the collaboration, Jefferson Health are piloting GDm-Health in their patients who develop diabetes during pregnancy.Jefferson Health has also supported Sensyne Health’s marketing efforts to secure wider adoption of GDm-Health across the US.The collaboration has now extended to include the identification of new market opportunities for all of Sensyne Health’s software products and input into product definition and design validation.

Outcomes

The work with Jefferson Health is central to Sensyne Health’s US go-to-market strategy for its software products including GDm-Health(monitoring diabetes in pregnancy), EDGE (monitoring chronic obstructive pulmonary disease at home) and Support-HF (monitoring heart failure at home). Additionally, the collaboration is expected to lead to the development of new product features and wholly new products that will benefit patients in the NHS as well as those in the US and other countries.

The products connect patients, clinicians and researchers, generating large databases of phenotypic data, and enabling discovery research to improve patient outcomes.This data will further enrich the clinical insights that Sensyne Health can provide to support the development of new therapeutics.

The work that Sensyne Health and JeffersonHealth are undertaking will provide a platform on which Sensyne Health’s distributor partner in the US can build a robust sales model.

Case study

Evaluating the potential for Sensyne in the US healthcare market – our collaboration with Jefferson Health

January 15, 2020

The US currently spends approximately 18%of its GDP on healthcare, compared to 10%in the UK. There are significant potential opportunities to introduce healthcare innovations that have been developed and validated by Sensyne Health, working in partnership with the NHS, to be exported to the US. In January 2019 Sensyne Health entered into a collaboration with Jefferson Health’s Strategic Ventures arm to undertake a clinical and health-economic evaluation of Sensyne Health’s digital health products to determine their potential in the US market.

Purpose

One of the largest healthcare providers in Pennsylvania and New Jersey and the fastest growing health system in the US, Philadelphia-based Jefferson Health, has 14 hospitals with 2,800 beds,6,000 physicians and 7,000nursing staff. The system includes the Sidney Kimmel Cancer Centre and is affiliated with the Thomas Jefferson University. JeffersonHealth has a track record of supporting digital health businesses seeking a route into the US market through collaboration and shares an interest in the target disease areas on which Sensyne Health is focused.

The work

As part of the collaboration, Jefferson Health are piloting GDm-Health in their patients who develop diabetes during pregnancy.Jefferson Health has also supported Sensyne Health’s marketing efforts to secure wider adoption of GDm-Health across the US.The collaboration has now extended to include the identification of new market opportunities for all of Sensyne Health’s software products and input into product definition and design validation.

Outcomes

The work with Jefferson Health is central to Sensyne Health’s US go-to-market strategy for its software products including GDm-Health(monitoring diabetes in pregnancy), EDGE (monitoring chronic obstructive pulmonary disease at home) and Support-HF (monitoring heart failure at home). Additionally, the collaboration is expected to lead to the development of new product features and wholly new products that will benefit patients in the NHS as well as those in the US and other countries.

The products connect patients, clinicians and researchers, generating large databases of phenotypic data, and enabling discovery research to improve patient outcomes.This data will further enrich the clinical insights that Sensyne Health can provide to support the development of new therapeutics.

The work that Sensyne Health and JeffersonHealth are undertaking will provide a platform on which Sensyne Health’s distributor partner in the US can build a robust sales model.

Case study

Evaluating the potential for Sensyne in the US healthcare market – our collaboration with Jefferson Health

Evaluating the potential for Sensyne in the US healthcare market – our collaboration with Jefferson Health

January 15, 2020

The US currently spends approximately 18%of its GDP on healthcare, compared to 10%in the UK. There are significant potential opportunities to introduce healthcare innovations that have been developed and validated by Sensyne Health, working in partnership with the NHS, to be exported to the US. In January 2019 Sensyne Health entered into a collaboration with Jefferson Health’s Strategic Ventures arm to undertake a clinical and health-economic evaluation of Sensyne Health’s digital health products to determine their potential in the US market.

Purpose

One of the largest healthcare providers in Pennsylvania and New Jersey and the fastest growing health system in the US, Philadelphia-based Jefferson Health, has 14 hospitals with 2,800 beds,6,000 physicians and 7,000nursing staff. The system includes the Sidney Kimmel Cancer Centre and is affiliated with the Thomas Jefferson University. JeffersonHealth has a track record of supporting digital health businesses seeking a route into the US market through collaboration and shares an interest in the target disease areas on which Sensyne Health is focused.

The work

As part of the collaboration, Jefferson Health are piloting GDm-Health in their patients who develop diabetes during pregnancy.Jefferson Health has also supported Sensyne Health’s marketing efforts to secure wider adoption of GDm-Health across the US.The collaboration has now extended to include the identification of new market opportunities for all of Sensyne Health’s software products and input into product definition and design validation.

Outcomes

The work with Jefferson Health is central to Sensyne Health’s US go-to-market strategy for its software products including GDm-Health(monitoring diabetes in pregnancy), EDGE (monitoring chronic obstructive pulmonary disease at home) and Support-HF (monitoring heart failure at home). Additionally, the collaboration is expected to lead to the development of new product features and wholly new products that will benefit patients in the NHS as well as those in the US and other countries.

The products connect patients, clinicians and researchers, generating large databases of phenotypic data, and enabling discovery research to improve patient outcomes.This data will further enrich the clinical insights that Sensyne Health can provide to support the development of new therapeutics.

The work that Sensyne Health and JeffersonHealth are undertaking will provide a platform on which Sensyne Health’s distributor partner in the US can build a robust sales model.

Case study

Evaluating the potential for Sensyne in the US healthcare market – our collaboration with Jefferson Health

Evaluating the potential for Sensyne in the US healthcare market – our collaboration with Jefferson Health

The US currently spends approximately 18%of its GDP on healthcare, compared to 10%in the UK. There are significant potential opportunities to introduce healthcare innovations that have been developed and validated by Sensyne Health, working in partnership with the NHS, to be exported to the US. In January 2019 Sensyne Health entered into a collaboration with Jefferson Health’s Strategic Ventures arm to undertake a clinical and health-economic evaluation of Sensyne Health’s digital health products to determine their potential in the US market.

Purpose

One of the largest healthcare providers in Pennsylvania and New Jersey and the fastest growing health system in the US, Philadelphia-based Jefferson Health, has 14 hospitals with 2,800 beds,6,000 physicians and 7,000nursing staff. The system includes the Sidney Kimmel Cancer Centre and is affiliated with the Thomas Jefferson University. JeffersonHealth has a track record of supporting digital health businesses seeking a route into the US market through collaboration and shares an interest in the target disease areas on which Sensyne Health is focused.

The work

As part of the collaboration, Jefferson Health are piloting GDm-Health in their patients who develop diabetes during pregnancy.Jefferson Health has also supported Sensyne Health’s marketing efforts to secure wider adoption of GDm-Health across the US.The collaboration has now extended to include the identification of new market opportunities for all of Sensyne Health’s software products and input into product definition and design validation.

Outcomes

The work with Jefferson Health is central to Sensyne Health’s US go-to-market strategy for its software products including GDm-Health(monitoring diabetes in pregnancy), EDGE (monitoring chronic obstructive pulmonary disease at home) and Support-HF (monitoring heart failure at home). Additionally, the collaboration is expected to lead to the development of new product features and wholly new products that will benefit patients in the NHS as well as those in the US and other countries.

The products connect patients, clinicians and researchers, generating large databases of phenotypic data, and enabling discovery research to improve patient outcomes.This data will further enrich the clinical insights that Sensyne Health can provide to support the development of new therapeutics.

The work that Sensyne Health and JeffersonHealth are undertaking will provide a platform on which Sensyne Health’s distributor partner in the US can build a robust sales model.

Arrange to meet us
Case study

Evaluating the potential for Sensyne in the US healthcare market – our collaboration with Jefferson Health

January 15, 2020

The US currently spends approximately 18%of its GDP on healthcare, compared to 10%in the UK. There are significant potential opportunities to introduce healthcare innovations that have been developed and validated by Sensyne Health, working in partnership with the NHS, to be exported to the US. In January 2019 Sensyne Health entered into a collaboration with Jefferson Health’s Strategic Ventures arm to undertake a clinical and health-economic evaluation of Sensyne Health’s digital health products to determine their potential in the US market.

Purpose

One of the largest healthcare providers in Pennsylvania and New Jersey and the fastest growing health system in the US, Philadelphia-based Jefferson Health, has 14 hospitals with 2,800 beds,6,000 physicians and 7,000nursing staff. The system includes the Sidney Kimmel Cancer Centre and is affiliated with the Thomas Jefferson University. JeffersonHealth has a track record of supporting digital health businesses seeking a route into the US market through collaboration and shares an interest in the target disease areas on which Sensyne Health is focused.

The work

As part of the collaboration, Jefferson Health are piloting GDm-Health in their patients who develop diabetes during pregnancy.Jefferson Health has also supported Sensyne Health’s marketing efforts to secure wider adoption of GDm-Health across the US.The collaboration has now extended to include the identification of new market opportunities for all of Sensyne Health’s software products and input into product definition and design validation.

Outcomes

The work with Jefferson Health is central to Sensyne Health’s US go-to-market strategy for its software products including GDm-Health(monitoring diabetes in pregnancy), EDGE (monitoring chronic obstructive pulmonary disease at home) and Support-HF (monitoring heart failure at home). Additionally, the collaboration is expected to lead to the development of new product features and wholly new products that will benefit patients in the NHS as well as those in the US and other countries.

The products connect patients, clinicians and researchers, generating large databases of phenotypic data, and enabling discovery research to improve patient outcomes.This data will further enrich the clinical insights that Sensyne Health can provide to support the development of new therapeutics.

The work that Sensyne Health and JeffersonHealth are undertaking will provide a platform on which Sensyne Health’s distributor partner in the US can build a robust sales model.